MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection
Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if HIV that persists despite current antiviral
therapy can be targeted by new treatments. We will see if adding Raltegravir (MK-0518) and
Valproic acid (VPA) to current ART can decrease the amount of latent HIV.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Abbott Merck Sharp & Dohme Corp. National Institute of Allergy and Infectious Diseases (NIAID)